Print Page  Close Window

Corporate Profile

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. The company’s Phase 2 STRIVE clinical trial of rezafungin met its primary safety and efficacy objectives, and Cidara plans to initiate Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prophylaxis of invasive fungal infections in 2018. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California.

Presentation

DateTitle
07/18/18
Download Documentation Corporate Presentation May 2018

Stock Information

CDTX (Common Stock)
PriceChange% ChangeVolume
$4.25 - 0.153.41%136,824
Previous CloseToday's OpenIntraday HighIntraday Low
$4.40$4.40$4.40$4.15
Exchange: NASDAQ (US Dollar)
08/15/18 2:14 p.m. ET
Refresh quote

 

Stock chart for: CDTX.O.  Currently trading at $4.25 with a 52 week high of $8.80 and a 52 week low of $3.65.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources